Moreover, in vivo administration of pan-HDAC inhibitors, givinostat and vorinostat (also known as suberanilohydroxamic acid, SAHA), results in an improved barrier recovery and epithelial wound healing in a dextran sodium sulfate (DSS)-induced mouse model of inflammatory bowel disease [60]. The gene discussed is HDAC9; the disease is inflammatory bowel disease.